Skip to main content
. Author manuscript; available in PMC: 2023 Dec 11.
Published in final edited form as: Pharmacol Res. 2023 Oct 14;197:106961. doi: 10.1016/j.phrs.2023.106961

Fig. 8.

Fig. 8.

(a) Chemical modification on fentanyl for development of lead bitopic ligands. (b) β-arrestin1 and β-arrestin2 recruitment to MOR measured for 10 μM agonist, using a BRET assay. (c) TRUPATH BRET concentration-response curves of G protein activation at MOR for fentanyl, C5 guano and C6 guano.

Material from: Faouzi et al. [24].